Fairfield Market Research Compounded Bioidentical Hormone Therapy Market Size 2030

Compounded Bioidentical Hormone Therapy Market

Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Published Date: Upcoming | Format:

Industry: Pharmaceuticals & Biotechnology


Request Customization Request Customization

This report intends to critically examine the global compounded bioidentical hormone therapy market, offering insights expected to aid in scrutinizing market growth over the forecasted timeline.

Market Analysis in Brief

The global compounded bioidentical hormone therapy market is a swiftly developing field involving the preparation and application of tailored hormone therapies. These therapies, designed using bioidentical hormones, are believed to offer benefits such as better symptom control and improved quality of life. Compounded bioidentical hormone therapy finds extensive applications across a broad range of treatments, including menopause, andropause, adrenal fatigue, and thyroid disorders. The growth of the compounded bioidentical hormone therapy market is projected to be significant due to the increasing demand for these treatments.

Key Report Findings

  • The global compounded bioidentical hormone therapy market was valued at over US$2 Bn in 2022
  • Bioidentical oestrogen therapy segment is projected to account for the largest market share
  • Menopause-related treatments are expected to account for the highest end-use segment
  • SottoPelle is a leading company in the compounded bioidentical hormone therapy market
  • North America is projected to be the largest regional market

Growth Drivers

Ageing populations, Personalised Treatments, and Increasing Awareness 

The compounded bioidentical hormone therapy market is experiencing substantial growth due to rising awareness and demand. Bioidentical hormone therapy (BHT) offers many advantages over traditional hormone replacement therapies, as it uses hormones with the same chemical structure as those naturally produced in the human body. This compatibility enhances safety and efficacy.

A key driver of this market is the ability of compounded bioidentical hormone therapy to offer personalised and customised treatment. By assessing each patient's hormone levels and specific needs, healthcare providers can compound tailored hormone formulations, addressing individual requirements. This personalised approach is highly appealing to patients and healthcare professionals looking for targeted and effective treatment options.

Additionally, ageing populations also contribute significantly toward market growth. As individuals age, hormonal imbalances become more prevalent, leading to various symptoms. Bioidentical hormone therapy presents a potential solution for alleviating these symptoms and enhancing the quality of life for ageing individuals. This therapy can effectively address menopausal symptoms in women or andropausal symptoms in men by restoring hormonal balance.

Furthermore, the market is also driven by a growing preference for natural and bio-identical treatments. Bioidentical hormones, derived from natural sources, closely resemble the body's natural hormones. This characteristic appeals to individuals looking for holistic and safer alternatives to synthetic hormones.

Advancements in compounding pharmacy practices and supportive regulations have also played crucial roles in market expansion. These advancements have improved the efficiency and accuracy of compounded hormone formulations, making them more accessible to both healthcare providers and patients. Factors such as this are slated to have a profound influence on the growth trajectory of the global compounded bioidentical hormone therapy market in the years ahead.

Growth Challenges

Limited Scientific Evidence, Regulatory Challenges, and a Lack of Standardisation

The compounded bioidentical hormone therapy market faces certain restraints that require careful consideration. One important aspect is the limited scientific evidence supporting the therapy's efficacy and long-term safety, indicating the need for more robust clinical studies. Additionally, navigating the varying regulatory landscape across different regions can be challenging, as compliance with regulations and maintaining quality standards are vital for compounding pharmacies.

While beneficial, the customisation of hormone formulations poses a standardisation challenge, making it difficult to establish consistent treatment protocols. Safety concerns and potential risks, though still being researched, need attention to ensure patient well-being. Limited insurance coverage and the presence of misinformation further affect this market. Overcoming these restraints will require collaborative efforts, research advancements, standardised education, and increased awareness among healthcare professionals and patients.

Growth Opportunities Across Regions

The compounded bioidentical hormone therapy market is divided into regions to understand its growth patterns better. North America, including the United States, and Canada, has a strong demand due to a growing ageing population and advanced healthcare facilities.

Countries like Germany, France, and the United Kingdom show promise with increased awareness and supportive regulations in Europe. The Asia Pacific region, including Japan, China, and India experiences rising demand driven by factors such as an ageing population and improved healthcare infrastructure.

Latin America, including Brazil, and Mexico, is developing its market for personalised healthcare options. The Middle East and Africa witness an emerging market, particularly in countries like the United Arab Emirates, and South Africa where healthcare infrastructure is growing, and awareness is increasing. The report would offer detailed insights into each region's specific breakdown of the market.

Key Market Players – Compounded Bioidentical Hormone Therapy Landscape

Key players in this market include SottoPelle, BioTE Medical, Belmar Pharmacy, and Advantage Pharmaceuticals. Key players in the global compounded bioidentical hormone therapy market have been involved in new product launches and are implementing other growth strategies such as collaborations and acquisitions to strengthen their respective market position.

Compounded Bioidentical Hormone Therapy Market: Key Developments

  • In 2020, BioTE Medical expanded its product line to include nutraceuticals designed to support hormone balance
  • In November 2020, Belmar Pharmacy launched a new custom compounding service for bioidentical hormone therapies
  • In January 2021, SottoPelle announced a new treatment for andropause using tailored hormone therapies
  • In May 2021, Advantage Pharmaceuticals entered a collaboration with a major healthcare provider to expand its bioidentical hormone

Regional Classification of the Global Compounded Bioidentical Hormone Therapy Market is Listed Below:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • Spain
  • U.K.
  • Italy
  • Russia
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

 Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East and Africa

  • GCC
  • South Africa
  • Rest of Middle East & Africa

1. Executive Summary
     1.1. Global Compounded Bioidentical Hormone Therapy Market Outlook, 2018 - 2030 (US$ Million)
     1.2. Global Compounded Bioidentical Hormone Therapy Market Incremental Opportunity, 2018 - 2030 (US$ Million)
     1.3. Key Industry Trends

2. Market Overview
     2.1. Market Definitions and Segmentations
     2.2. Market Dynamics
            2.2.1. Drivers
                  2.2.1.1. Driver 1
                  2.2.1.2. Driver 2
            2.2.2. Restraints
                  2.2.2.1. Restraint 1
                  2.2.2.2. Restraint 2
            2.2.3. Market Opportunities Matrix
     2.3. Regulatory Guidelines
     2.4. Reimbursement Scenario
     2.5. Covid-19 Impact Analysis

3. Global Compounded Bioidentical Hormone Therapy Market Outlook, 2018 - 2030
     3.1. Global Compounded Bioidentical Hormone Therapy Market Outlook, by Hormone Type, Value (US$ Mn), 2018 - 2030
            3.1.1. Key Highlights
                  3.1.1.1. Progesterone
                  3.1.1.2. Estrogen
                  3.1.1.3. Testosterone
                  3.1.1.4. Other
            3.1.2. BPS Analysis/Market Attractiveness Analysis

4. Global Compounded Bioidentical Hormone Therapy Market Outlook, 2018 - 2030
     4.1. Global Compounded Bioidentical Hormone Therapy Market Outlook, by Delivery Method, Value (US$ Mn), 2018 - 2030
            4.1.1. Key Highlights
                  4.1.1.1. Tablets & Capsules
                  4.1.1.2. Injection
                  4.1.1.3. Patches
                  4.1.1.4. Gels
                  4.1.1.5. Inserts
                  4.1.1.6. Pellets
                  4.1.1.7. Others
            4.1.2. BPS Analysis/Market Attractiveness Analysis
     4.2. Global Compounded Bioidentical Hormone Therapy Market Outlook, by Region, Value (US$ Mn), 2018 - 2030
            4.2.1. Key Highlights
                  4.2.1.1. North America
                  4.2.1.2. Europe
                  4.2.1.3. Asia Pacific
                  4.2.1.4. Rest of the World
            4.2.2. BPS Analysis/Market Attractiveness Analysis

5. North America Compounded Bioidentical Hormone Therapy Market Outlook, 2018 - 2030
     5.1. North America Compounded Bioidentical Hormone Therapy Market Outlook, by Hormone Type, Value (US$ Mn), 2018 - 2030
            5.1.1. Key Highlights
                  5.1.1.1. Progesterone
                  5.1.1.2. Estrogen
                  5.1.1.3. Testosterone
                  5.1.1.4. Other
            5.1.2. BPS Analysis/Market Attractiveness Analysis
     5.2. North America Compounded Bioidentical Hormone Therapy Market Outlook, by Delivery Method, Value (US$ Mn), 2018 - 2030
            5.2.1. Key Highlights
                  5.2.1.1. Tablets & Capsules
                  5.2.1.2. Injection
                  5.2.1.3. Patches
                  5.2.1.4. Gels
                  5.2.1.5. Inserts
                  5.2.1.6. Pellets
                  5.2.1.7. Other
            5.2.2. BPS Analysis/Market Attractiveness Analysis
     5.3. North America Compounded Bioidentical Hormone Therapy Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
            5.3.1. Key Highlights
                  5.3.1.1. U.S.
                  5.3.1.2. Canada
            5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Europe Compounded Bioidentical Hormone Therapy Market Outlook, 2018 - 2030
     6.1. Europe Compounded Bioidentical Hormone Therapy Market Outlook, by Hormone Type, Value (US$ Mn), 2018 - 2030
            6.1.1. Key Highlights
                  6.1.1.1. Progesterone
                  6.1.1.2. Estrogen
                  6.1.1.3. Testosterone
                  6.1.1.4. Other
            6.1.2. BPS Analysis/Market Attractiveness Analysis
     6.2. Europe Compounded Bioidentical Hormone Therapy Market Outlook, by Delivery Method, Value (US$ Mn), 2018 - 2030
            6.2.1. Key Highlights
                  6.2.1.1. Tablets & Capsules
                  6.2.1.2. Injection
                  6.2.1.3. Patches
                  6.2.1.4. Gels
                  6.2.1.5. Inserts
                  6.2.1.6. Pellets
                  6.2.1.7. Others
            6.2.2. BPS Analysis/Market Attractiveness Analysis
     6.3. Europe Compounded Bioidentical Hormone Therapy Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
            6.3.1. Key Highlights
                  6.3.1.1. Germany
                  6.3.1.2. France
                  6.3.1.3. U.K.
                  6.3.1.4. Italy
                  6.3.1.5. Spain
                  6.3.1.6. Rest of Europe
            6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Asia Pacific Compounded Bioidentical Hormone Therapy Market Outlook, 2018 - 2030
     7.1. Asia Pacific Compounded Bioidentical Hormone Therapy Market Outlook, by Hormone Type, Value (US$ Mn), 2018 - 2030
            7.1.1. Key Highlights
                  7.1.1.1. Progesterone
                  7.1.1.2. Estrogen
                  7.1.1.3. Testosterone
                  7.1.1.4. Other
            7.1.2. BPS Analysis/Market Attractiveness Analysis
     7.2. Asia Pacific Compounded Bioidentical Hormone Therapy Market Outlook, by Delivery Method, Value (US$ Mn), 2018 - 2030
            7.2.1. Key Highlights
                  7.2.1.1. Tablets & Capsules
                  7.2.1.2. Injection
                  7.2.1.3. Patches
                  7.2.1.4. Gels
                  7.2.1.5. Inserts
                  7.2.1.6. Pellets
                  7.2.1.7. Others
            7.2.2. BPS Analysis/Market Attractiveness Analysis
     7.3. Asia Pacific Compounded Bioidentical Hormone Therapy Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
            7.3.1. Key Highlights
                  7.3.1.1. China
                  7.3.1.2. Japan
                  7.3.1.3. India
                  7.3.1.4. Australia & New Zealand
                  7.3.1.5. Rest of Asia Pacific
            7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Rest of the World Compounded Bioidentical Hormone Therapy Market Outlook, 2018 - 2030
     8.1. Rest of the World Compounded Bioidentical Hormone Therapy Market Outlook, by Hormone Type, Value (US$ Mn), 2018 - 2030
            8.1.1. Key Highlights
                  8.1.1.1. Progesterone
                  8.1.1.2. Estrogen
                  8.1.1.3. Testosterone
                  8.1.1.4. Other
            8.1.2. BPS Analysis/Market Attractiveness Analysis
     8.2. Rest of the World Compounded Bioidentical Hormone Therapy Market Outlook, by Delivery Method, Value (US$ Mn), 2018 - 2030
            8.2.1. Key Highlights
                  8.2.1.1. Tablets & Capsules
                  8.2.1.2. Injection
                  8.2.1.3. Patches
                  8.2.1.4. Gels
                  8.2.1.5. Inserts
                  8.2.1.6. Pellets
                  8.2.1.7. Others
            8.2.2. BPS Analysis/Market Attractiveness Analysis
     8.3. Rest of the World Compounded Bioidentical Hormone Therapy Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
            8.3.1. Key Highlights
                  8.3.1.1. Latin America
                  8.3.1.2. Middle East & Africa
            8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape
     9.1. Company Market Share Analysis
     9.2. Company Profiles
            9.2.1. The London Specialist Pharmacy
                  9.2.1.1. Company/Pharmacy Overview
                  9.2.1.2. Financial Overview
                  9.2.1.3. Product Portfolio
                  9.2.1.4. Recent Developments
*Above details will include, but not be limited to below list of companies based on availability
            9.2.2. Biote
            9.2.3. Neuva Aesthetics
            9.2.4. Pellecome LLC
            9.2.5. The Biostation
            9.2.6. RevitaLife
            9.2.7. Therapeutics MD
            9.2.8. Tutera Medical, Inc.
            9.2.9. Others

10. Appendix
     10.1. Research Methodology
     10.2. Report Assumptions
     10.3. Acronyms and Abbreviations

Our Research Methodology

Considering the volatility of business today, traditional approaches to strategizing a game plan can be unfruitful if not detrimental. True ambiguity is no way to determine a forecast. A myriad of predetermined factors must be accounted for such as the degree of risk involved, the magnitude of circumstances, as well as conditions or consequences that are not known or unpredictable. To circumvent binary views that cast uncertainty, the application of market research intelligence to strategically posture, move, and enable actionable outcomes is necessary.

View Methodology
Fairfield Quality assured
Fairfield Confidentiality assured
Fairfield Custom research services